Remegen eyes competitive DMT market as telitacicept shows promise in gMG: GlobalData GlobalData Apr 14, 2025 With positive Phase III data in AChR+ and MuSK+ gMG, Remegen’s telitacicept enters a crowded DMT space, aiming to stand out…
